Monitoring Adverse Events Following CAR T-Cell Therapy

Opinion
Video

A panel of oncologists in academic and community settings discuss patient monitoring practices following CAR T-cell infusions, with a focus on neurotoxicities.

  • Dr. Usmani: What is your protocol for monitoring and grading of neurotoxicity, cytokine release syndrome (CRS), and other acute toxicities immediately following CAR-T cell infusion?
    1. Are there any subgroups of patients you have found to be at particularly high risk for delayed neurotoxicity requiring extended monitoring?
    2. What are your institutional guidelines around administering steroids, anti-seizure medications, or other treatments for severe neurotoxicity?
Recent Videos
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD
4 KOLs are featured in this panel.
4 KOLs are featured in this panel.
2 KOLs are featured in this series
2 KOLs are featured in this series
A panel of 4 experts on multiple myeloma
Related Content